Gemtero 200gm Injection

Gemtero 200gm Injection is used in the treatment of many cancers such as non-small cell lung cancer, breast cancer, pancreatic cancer, urinary bladder cancer and ovarian cancer.

Uses of Gemtero 200gm Injection:

• Non-small cell lung cancer.
• Pancreatic cancer.
• Breast cancer
• Bladder cancer

How does a Gemtero 200gm Injection work?

Gemcitabine is a nucleoside analog that interferes with DNA synthesis. This blocks DNA polymerase and thus prevents DNA strand elongation. Which prevents apoptosis (programmed cell death) and cell cycle halt and integrate into DNA.

How to Use & Dosage

Administered by IV infusion over a specific period, typically 30 minutes. It depends on the type of cancer and the treatment protocol.

This medicine is given by infusion into a vein. It is given in a hospital or clinic by a medical expert with special training.

Talk to your doctor about the use of this medicine in children. Additional caution may be necessary.

If you think you may have taken too much of this medication, call your emergency room or poison control center at once.

Possible Side Effects:

• Myelosuppression
• Nausea
• Vomiting
• Fatigue
• Liver enzyme elevation
• Flu-like symptoms
• Fever
• Chills

Safety Advise:

🫘 Kidney

Gemtero 200gm Injection should NOT be used in people who have kidney problems. Please speak with your healthcare provider.

🟤 Liver

This medicine may cause serious problems if you have liver disease. Consult your health care provider.

🤰 Pregnancy

Gemtero 200gm injections when pregnant is dangerous which affects the growing fetus Please speak to your healthcare provider.

🤱 Breastfeeding

Gemtero 200gm Injection may cause serious side effects during breastfeeding. Talk to your healthcare provider.

🍷 Alcohol

Taking Gemtero 200gm with alcohol injection may cause extreme sleepiness. Please see your health care provider.

Storage Instructions:

Store in a cool, dry place away from light.

References

Eli Lilly and Company. GEMZAR (Gemcitabine) for Injection: Highlights of Prescribing Information. U.S. Food and Drug Administration.

Burris HA, Moore MJ, Andersen J, et al. Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer. Journal of Clinical Oncology. 1997;15(6):2403-2413.

Sandler AB, Nemunaitis J, Denham C, et al. Phase III Trial of Gemcitabine Plus Cisplatin versus Cisplatin Alone in Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2000;18(1):122-130.

Brunton LL, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education.

Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.